The current Chronic Inflammatory Demyelinating Polyneuropathy Market Size was valued at USD 1.996 billion in 2024, showcasing its status as a high-value niche market within neurology, despite the relatively low patient population. This high valuation is a direct consequence of the continuous and expensive nature of its core plasma-derived therapies, which are essential for preventing severe disability.

The projection for the Chronic Inflammatory Demyelinating Polyneuropathy Market Size to reach USD 4.332 billion by 2035 is fueled by anticipated market penetration in emerging economies and the premium pricing of next-generation biologic drugs currently in clinical trials. Successful launches of these innovative, targeted therapies are expected to be the key factor in realizing the upper bounds of this impressive forecast growth.